Preimplantation genetic screening using fluorescence in situ hybridization in patients with repetitive implantation failure and advanced maternal age: two randomized trials

Preimplantation genetic screening using fluorescence in situ hybridization improves live-birth rates in patients with repetitive implantation failure or advanced maternal age.

Like Comment


Carmen Rubio, Ph.D., José Bellver, M.D, Ph.D., Lorena Rodrigo, M.Sc., Ernesto Bosch, M.D, Ph.D., Amparo Mercader, Ph.D., Carmen Vidal, M.D, Ph.D., Maria José De los Santos, Ph.D., Juan Giles, M.D., Elena Labarta, M.D., Javier Domingo, M.D., Juana Crespo, M.D., José Remohí, M.D, Ph.D., Antonio Pellicer, M.D, Ph.D, Carlos Simón, M.D, Ph.D.

Volume 99, Issue 5, Pages 1400-1407, April 2013



To evaluate the usefulness of Preimplantation Genetic Screening (PGS) using fluorescence in situ hybridization (FISH) for two different indications: repetitive implantation failure (RIF) and advanced maternal age (AMA).


Two prospective randomized trials (RCTs) with patients allocated in two arms: blastocyst transfer on day 5 (group A) or PGS with transfer on day 5 (group B).


University-affiliated private clinics.


The RIF study included women <40 years with ≥3 failed IVF cycles without other known causal factors (91 patients). The AMA study included ICSI patients aged between 41 and 44 years (183 patients). Interventions:

In the PGS group, single cell day-3 biopsy was performed with aneuploidy screening for chromosomes 13, 15, 16, 17, 18, 21, 22, X, and Y. In both the blastocyst transfer group and the PGS group, embryo transfer was performed on day 5.

Main outcome measure(s):

Live birth rate per patient and per started cycle.


A significant increase in live birth rates per patient was found in the PGS group compared to the blastocyst group for the AMA study (30/93 patients (32.3%) vs.14/90 patients (15.5%); OR 2.585 CI [1.262-5.295]). In the RIF study no significant differences were observed (23/48 patients (47.9%) vs. 12/43 patients (27.9%).


PGS with FISH was shown to be beneficial for the AMA group.

Read the full text at:

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.